An observational study in Role of Neurofilment in Diagnosis of Multiple Sclerosis, sponsored by Assiut University. Enrolling by invitation at 1 site in Egypt. Open to participants aged 16 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-09.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cognitive Dysfunction by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Cognitive Dysfunction · Assiut University.
Among the 10 studies in Cognitive Dysfunction by Assiut University, this one is the only one that started in 2023, is one of 8 observational ones, and was the 5th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →6 of the 10 studies in Cognitive Dysfunction by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 50+ · Healthy volunteers
Assiut University
Ages 18–45
Assiut University
Ages 65+
Assiut University
Ages 18+
Assiut University
Ages 18–40 · Healthy volunteers
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 16 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 85 is below the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 64 across the 2 interventional studies, 80 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Cognitive Dysfunction by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678918Assiut UniversityCognitive Function and Quality of Life in Obstructive Sleep Apnea | 2027-08 |
| NCT07842679Assiut UniversityCognitive Impairment in Older Adults With Hematologic Malignancies | 2027-09-26 |
| NCT07852052Assiut UniversitySleep Architecture, Cognitive Function, and Quality of Life During Early Recovery From Substance Use Disorder | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Cognitive Dysfunction by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neurofilament protein detected in the serum appears to be a good marker for the extent of active neurodegeneration. Chitinase may also be a good marker reflecting the degree of astrocyte activation, or damage in active lesions (Paul et al, 2018).These markers have some clinical value for diagnosis and monitoring of disease activity. NfL can be objectively measured and quantified, it is highly sensitive to neurodegenerative processes and its concentration changes as the disease worsens or improves (Disanto et al., 2017). Numerous studies have shown that NfL levels increase during MS relapses and correlate with MRI lesion development (Disanto et al., 2016, 2017; Novakova et al., 2017), disease activity, (Thebault et al., 2020). Cognitive impairment is common in the early stages of multiple sclerosis, mainly affecting attention, working memory, and information processing speed, but also memory, inhibition, and conceptualisation. Poor performance is common but remains subtle and does not significantly affect the quality of life at this stage. However, many studies shows that these deficits reflect the destruction both within and outside lesions, and that they may therefore be considered as a severity marker in the early stages of multiple sclerosis. (Lengenfelder et al., 2005).
The aim of the work is to detect the role of serum NFL and chitinase as biomarkers in the diagnosis and prognosis of newly diagnosed multiple sclerosis patients, and to estimate the incidence of cognitive impairment and their relationship with the NFL in newly diagnosed MS patients.
Many immunological studies have been performed with the aim to identify MS specific biomarkers and disease mechanisms and to find markers able to predict clinical disease course and outcome (Housley et al, 2015) Besides MRI and markers related to therapy (induction of blocking antibodies) or JC virus infection, they include markers for neurodegeneration, such as neurofilaments, markers for astrocytic activation (eg. chitinase or GFAP). Neurofilament protein detected in the serum or cerebrospinal fluid appears to be a good marker for the extent of active neurodegeneration, but this is not MS specific. Chitinase may be a good marker for active disease in RRMS, reflecting the degree of astrocyte activation, or damage in active lesions (Paul et al, 2018).These markers have some clinical value for diagnosis and monitoring of disease activity. Cognitive impairment is common in the early stages of multiple sclerosis, mainly affecting attention, working memory, and information processing speed, but also memory, inhibition, and conceptualisation. Poor performance is common but remains subtle and does not significantly affect the quality of life at this stage. However, many studies shows that these deficits reflect the destruction both within and outside lesions, and that they may therefore be considered as a severity marker in the early stages of multiple sclerosis. (Lengenfelder et al., 2005).Aim of the work The aim of the work is to detect the role of serum neurofilament light chain and chitinase as well as cognitive impairment as biomarkers in the diagnosis and prognosis of newly diagnosed multiple sclerosis patients, and to estimate the incidence of cognitive impairment and their relationship with the NFL in newly diagnosed MS patients.Study Design This study is a cross-sectional, prospective, observational study. Subjects All newly diagnosed cases With MS patients attending different MS unites in Assiut governorate will be recruited and all eligible patients will be included.
Inclusion criteria:
All patients newly diagnosed MS according to the 2017-McDonalds criteria.
Exclusion criteria:
Patients who will meet the inclusion and exclusion criteria will be assessed in the 1st visit by direct interview followed by clinical examination and neuropsychological assessments as well as laboratory assessment. Baseline MRI scans will be obtained at the first visit and 12 months. In the follow up visits every 6 months for 1and half year at least with assessment for all previous will be repeated to detect early signs of progression.Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...):
Demographic data: age at presentation and age at onset, sex, education years and special habits Clinical data: duration of illness, until diagnosis number of relapses/year and their features.
Clinical assessment: EDSS, 9-hole pig test, 25-feet walking test.
Clinical rating scales :
Cognitive assessment using the Brief International Cognitive Assessment for Multiple sclerosis (BICAMS) with the Arabic validated version (8) that include:
Symbol Digit Modalities Test (SDMT) (Langdon et al. 2012) for evaluating the information processing speed.
California Verbal Learning Test (CVLT-II) for evaluating verbal learning and memory.
Brief Visual Memory Test (BVMT) for evaluating visual learning and memory.
Multiple sclerosis Quality of life MSQoL-54 questionnaire (10) with sub scales that measures physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function.
Hamilton depression rating-17-item version (HAM-D 17).
Laboratory investigation:
CSF Oligoclonal band, Serum light chain Neurofilament using PCR Research outcomes The primary outcome is the detection of neurofilament as diagnostic and prognostic inflammatory markers in newly diagnosed MS patients.
Secondary outcome measure is incidence of depression, cognitive impairment in newly diagnosed MS patients.
Follow up of each patient every 6 months using the same previous scales
Naïve Patients who will meet the inclusion and exclusion criteria of MS will be assessed in the 1st visit by direct interview followed by clinical examination and neuropsychological assessments as well as laboratory assessment. Baseline MRI scans will be obtained at the first visit and 12, months follow up. In the follow up visits every 6 months for 1and half year at least with assessment for all previous will be repeated to detect early signs of progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients newly diagnosed MS according to the 2017-McDonalds criteria.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The primary outcome is the detection of neurofilament light chain as diagnostic and prognostic inflammatory markers in newly diagnosed MS patients.
Assessment of the serum level of NFL at base line before starting DMT and correlate it with motor disability, cognitive impairment after one and half year
Time frame: 1 and half year
Assessment of the incidence of cognitive impairment among naive multiple sclerosis patients and their correlation with neurofilment light chain
Assessment of cognitive impairment of the MS Patients using BICAMS
Time frame: 1 and half year
Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 12 months is below that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.